期刊
CLINICAL CANCER RESEARCH
卷 27, 期 20, 页码 5647-5659出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-0161
关键词
-
类别
资金
- North West Cancer Research Fund (NWCR) [CR1041, CR1179]
- Cancer Research UK (CRUK) [C2750/A23669]
- Kay Kendall Leukaemia Fund [KKL1174]
- Leukaemia UK John Goldman Fellowship for Future Science [:153896]
- Royal Embassy of Saudi Arabia Cultural Bureau
This study employed a high-resolution approach to investigate the impact of BCR signaling in CLL cells, revealing patient-specific kinase signatures and adaptive signaling reprogramming. This provides new insights into the effects of therapy on signaling response.
Purpose: B-cell receptor (BCR) signaling is critical for the pathogenesis of chronic lymphocytic leukemia (CLL), promoting both malignant cell survival and disease progression. Although vital, understanding of the wider signaling network associated with malignant BCR stimulation is poor. This is relevant with respect to potential changes in response to therapy, particularly involving kinase inhibitors. In the current study, we describe a novel highresolution approach to investigate BCR signaling in primary CLL cells and track the influence of therapy on signaling response. Experimental Design: Akinobead/mass spectrometry-based protocol was used to study BCR signaling in primary CLL cells. Longitudinal analysis of samples donated by clinical trial patients was used to investigate the impact of chemoimmunotherapy and ibrutinib on signaling following surface IgM engagement. Complementary Nanostring and immunoblotting analysis was used to verify our findings. Results: Our protocol isolated a unique, patient-specific signature of over 30 kinases from BCR-stimulated CLL cells. This signature was associated with 13 distinct Kyoto Encyclopedia of Genes and Genomes pathways and showed significant change in cells from treatment-naive patients compared with those from patients who had previously undergone therapy. This change was validated by longitudinal analysis of clinical trials samples where BCR-induced kinome responses in CLL cells altered between baseline and disease progression in patients failing chemoimmunotherapy and between baseline and treatment in patients taking ibrutinib. Conclusions: These data comprise the first comprehensive proteomic investigation of the BCR signaling response within CLL cells and reveal unique evidence that these cells undergo adaptive reprogramming of this signaling in response to therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据